Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAY 2586116 single ascending intravenous dose study in healthy male volunteers
NL-OMON49427Completed
- Sponsor
- Bayer
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, single-blind trial in obstructive sleep apnea hypopnea syndrome (OSAHS) comparing BAY 2586116 intravenous infusion with Placebo intravenous infusion (2 arms). Primary endpoints: Pharmacokinetics of BAY 2586116 after ascending intravenous doses and Safety and tolerability of BAY 2586116 after ascending intravenous doses. Started Jan 2021; status: completed.
02
Drugs
BAY2586116
03
Conditions
obstructive sleep apnea hypopnea syndrome (OSAHS)
Beyond the preview
Go deeper on NL-OMON49427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49427.